How many employees does FibroGen have this year?
FibroGen has 599 undefined employees this year.
FibroGen Employees 2024
FibroGen Employees
599
Ticker
FGEN
ISIN
US31572Q8087
WKN
A12EZ0
In 2024, FibroGen employed 599 people, a 0% change from the 599 number of employees in the previous year.
FibroGen Aktienanalyse
What does FibroGen do?
FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining FibroGen's Employee Base
FibroGen's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding FibroGen's operational capacity and future potential.
Year-to-Year Comparison
Assessing FibroGen's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
FibroGen's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in FibroGen’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about FibroGen stock
How many employees did FibroGen have compared to the previous year?
Compared to the previous year, FibroGen had 0% more employees.
What impact did the number of employees have on the company FibroGen?
The number of employees has a direct impact on the efficiency and productivity of FibroGen. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of FibroGen?
The number of employees can also have an impact on investors of FibroGen, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of FibroGen affect the company?
An increase in equity of FibroGen can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in FibroGen's equity affect the company?
A reduction in equity of FibroGen can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of FibroGen?
Some factors that can influence the equity of FibroGen include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of FibroGen so important for investors?
The equity of FibroGen is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at FibroGen influence the company?
The number of employees at FibroGen can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at FibroGen evolved in recent years?
In recent years, the number of employees at FibroGen has changed by 0.
How many employees does FibroGen currently have?
FibroGen currently has 599 undefined employees.
Why is the number of employees important for investors of FibroGen?
The number of employees is important for investors of FibroGen as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can FibroGen take to change the number of employees?
To change the number of employees, FibroGen can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does FibroGen pay?
Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.
What is the dividend yield of FibroGen?
The current dividend yield of FibroGen is .
When does FibroGen pay dividends?
FibroGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of FibroGen?
FibroGen paid dividends every year for the past 0 years.
What is the dividend of FibroGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is FibroGen located?
FibroGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of FibroGen from 10/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.
When did FibroGen pay the last dividend?
The last dividend was paid out on 10/22/2024.
What was the dividend of FibroGen in the year 2023?
In the year 2023, FibroGen distributed 0 USD as dividends.
In which currency does FibroGen pay out the dividend?
The dividends of FibroGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The FibroGen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von FibroGen
Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
